To compare effects of bright light therapy (BLT) alone or combined with the selective serotonin reuptake inhibitor (SSRI) fluoxetine, on severity of depression, circadian rhythms, mood disturbance, and sleep quality, in patients with non-seasonal depression. Patients and methods: Drug-free patients who were administered 10,000 lux of BLT for 30 minutes for 7 days comprised the BLT group (n = 7), while patients who started fluoxetine as an add-on treatment day comprised the SSRI + BLT group (n = 8). The primary outcomes were severity of depression, measured using the Hamilton Depression Rating Scale (HAM-D) and the Beck Depression Inventory (BDI); chronotype, measured using the Morningness Eveningness Questionnaire (MEQ); mood disturbance, measured using the Profile of Mood States (POMS) survey; and sleep quality, measured using the Pittsburgh Sleep Quality Index (PSQI), before and after treatment in both groups. Results: All patients completed the study, and none reported obvious side effects. The mean onset age of depression was 26.1 years ± 5.3 years in the BLT group and 27 years ± 9.5 years in the SSRI + BLT group (P = 0.425). The number of past depressive episodes was 1.29 ± 0.76 in the BLT group, and 1.5 ± 0.8 in the SSRI + BLT group (P = 0.427). The difference between pre-and posttreatment scores revealed no significant difference between groups for the HAM-D scale, BDI, MEQ, POMS survey, and the PSQI. Conclusion: This study suggests that BLT is effective with respect to the severity of depression, circadian rhythms, mood disturbance, and sleep quality, in non-seasonal depression. However, there was no evidence in favor of adjunctive fluoxetine with BLT in the treatment of non-seasonal depression, for any of the rating scales used in our study.
Introduction
The beneficial effect of bright light therapy (BLT) in seasonal affective disorder (SAD) either alone or as an add-on therapy to antidepressant drugs is well accepted, with early onset of action and mild adverse-effect profiles. 1 However, the effect of BLT in non-seasonal depression has been controversial. While some controlled studies reported significant improvements, 2 others failed to do so. 3 Even if the improvement may be less than those seen in SAD, it can be assumed that at least some patients with non-seasonal depression respond to BLT. 4 Recent research also suggested that the use of BLT might be useful as an adjunctive treatment to antidepressants in non-seasonal depression, both in terms of results from clinician-rated depression scales and results from patient-reported symptom and well-being scales. 5 Sleep disturbances are common among depressive patients, and abnormalities of sleep architecture constitute the most robust psychobiological correlates of major depression. From a clinical perspective, there is an association between sleep problems and depression. 6 The relationship between sleep-related breathing disorders and depressive symptoms was shown in a population of school-aged children, by Carotenuto et al. 7 Also, sleep disturbance in adolescence has been associated with adult mental health problems, such as depression and substance abuse. 8 Disturbed sleep (insomnia and/or hypersomnia) has been included as one of the nine diagnostic criteria for major depressive episodes in the DSM-III, DSM-III-R, and DSM-IV. Sleep fragmentation, decreased quantity and altered distribution of delta sleep, reduced duration of the first non−rapid eye movement (REM) period (ie, REM latency), redistribution of REM sleep into the first half of the night, and increased number of REMs per minute of REM sleep were also shown by clinical study. 9 These symptoms have been related to impaired functioning of the suprachiasmatic nucleus (SCN). Activation of the SCN has been hypothesized as one of the mechanisms of BLT action on mood, sleep, circadian rhythms, and hypothalamic−pituitary axis activity. 10 Light induces specialized light-sensitive retinal ganglion cells to release glutamate in the SCN, through a monosynaptic pathway called the retinohypothalamic tract. 11 BLT also targets depression-associated neurotransmitter systems (serotonin, noradrenalin, and dopamine) and targets the same brain structures as antidepressant drug treatments. 12 The aim of the present study was to compare effects of BLT alone or combined with a selective serotonin reuptake inhibitor (SSRI) on the severity of depression, circadian rhythms, mood disturbance, and sleep quality, in patients with non-seasonal depression.
Patients and methods

Study population and design
The study was approved by the clinical research ethics board at the research center, Üsküdar University, Istanbul, Turkey and executed in accordance with the Helsinki Declaration. Subjects were assured that patient anonymity should be strictly preserved. After giving written, informed consent, eligible subjects entered a 1-week baseline phase without treatment to regularize their sleep−wake schedule (patients were instructed to sleep only between the hours of 10:00 pm and 8:00 am).
Drug-free patients who were administered 10,000 lux of BLT for 30 minutes for 7 days comprised the BLT group. Patients who were started on fluoxetine 20 mg/day and 10,000 lux of BLT for 30 minutes for 7 days as an add-on treatment comprised the SSRI + BLT group. The patients were randomly allocated into the two groups by means of a computer-generated random number list.
The inclusion criteria for the study were age between 18−65 years of age and major depressive episodes with a nonseasonal pattern. Depression was diagnosed using the Structured Clinical Interview for DSM-IV Axis I Disorders, Turkish clinical version. 13 The severity of depression was rated using the Structured Interview Guide for the Hamilton Scale for Depression (HAM-D). 14 Subjects were required to have an initial assessment score of 14 or higher on the 17-item HAM-D Scale, Turkish version, which indicates moderate to severe depression.
Subjects were excluded from the study if they: (1) were pregnant or lactating (or were sexually active women of childbearing potential not using a medically accepted means of contraception); (2) were at serious suicidal risk in the judgment of the investigator; (3) met the DSM-IV criteria for organic mental disorders or other major psychiatric disorder; (4) had a serious unstable medical illness; (5) had retinal disease or a family history that precluded the use of bright light; (6) had a history of severe allergies or multiple drug adverse reactions; (7) were currently using other psychotropic drugs, including lithium, L-tryptophan, or melatonin; (8) were currently using beta blocking drugs; (9) were previously treated with light therapy; or if (10) they performed shift work or traveled south during the protocol.
Bright light therapy administration
The active light treatment consisted of daily exposure to a white fluorescent light box (SADelite Daylight 10000; Northern Light Technologies, Montreal, QC, Canada) fitted with an ultraviolet filter and rated at 10,000 lux at a distance of 60-80 cm from screen to cornea, for 30 minutes as soon as possible after awakening and between 7:00 am and 8:00 am. The patients were advised not to stare directly into the light source and that the light should meet the eye at an angle of 30°-60°. The duration of therapy was 7 days for all participants. Patients were given verbal instructions on the use of the light box, and health care personnel attended all sessions.
Outcome parameters
Assessments were performed at the following two time points: just before the start of light treatment, and immediately on completion of the 1-week treatment interval. The primary outcome measures were as follows:
The HAM-D is a worldwide used clinician-administered rating scale for the evaluation of depression severity. 14 Though it exists in different versions with up to 36 items, the 17-item version is the most frequently used and meets established criteria for reliability and validity. The present study used the more structured 17-item version. 15 The scores on the first 14 items are based on a semistructured interview of the patient, interrogating their experiences over the previous week. The scores on the last three items (Insight, Psychomotor Retardation, and Psychomotor Agitation) are based on observations of the patient's behavior during the interview session. • Beck Depression Inventory Scale (BDI): The BDI is a commonly used 21-item measure of depression. 16 Each item consists of four statements describing increasing intensities of symptoms of depression. Items are rated on a scale from 0-3, reflecting how participants have felt over the past week. Possible scores range from 0-48; higher scores reflect more severe depressive symptoms. • Morningness Eveningness Questionnaire (MEQ): The MEQ measures chronotype (or circadian rhythms) by self-rated preference for the morning versus the evening hours. 17 In studies of clinically depressed men and women, depressed patients had lower MEQ scores (greater "eveningness") than nondepressed controls. 18 • Profile of Mood States Survey (POMS): The POMS is an easily completed 5-point mood adjective checklist. It is specifically intended for use as a research instrument for assessing changes in affective states across events or interventions in psychologically healthy adults. 19 The 65 items form six subscales, five negative mood states, and a single positive mood dimension. It is also possible to calculate a total score of mood disturbance, known as the POMS total, by summing the scores of the five subscales for the negative mood states and subtracting from this the score for the positive subscale. The five negative mood state subscales are tension-anxiety, depression-dejection, anger-hostility, fatigue-inertia, and confusion-bewilderment. The single positive mood state subscale is vigor-activity. • Pittsburgh Sleep Quality Index (PSQI): PSQI is a selfrated questionnaire designed specifically to measure sleep quality in clinical populations; it yields seven component scores and a global score. 20 The seven components are subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. As the questions in PSQI are related to usual sleep habits during the previous month, we modified the time interval from "last month" to "last week." Additionally, at baseline and at the end of the study, patients were systematically interviewed about possible adverse effects.
Statistical analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS) software version 19.0 for Windows (IBM, Armonk, NY, USA). A normal distribution of the quantitative data was checked using the Kolmogorov−Smirnov test. Parametric tests were applied to data of normal distribution and nonparametric tests were applied to data of questionably normal distribution. The independent samples t-test was used to compare independent groups. The data were expressed as mean ± standard deviation or median (interquartile range), as appropriate. Statistical significance was assumed for P , 0.05.
Results
Seven drug-free patients (one male, six females; mean age 28.4 ± 5.2 years) comprised the BLT group, while eight patients (two males, six females; mean age 28.9 ± 11.2 years) who were started on fluoxetine comprised the SSRI + BLT group. All patients completed the study. None reported obvious side effects, and none dropped out of the treatment protocol. BLT and fluoxetine were well tolerated. There were no hospitalizations or suicides during the study period. The mean onset age of depression was 26.1 ± 5.3 years in the BLT group and 27 ± 9.5 years in the SSRI + BLT group. The number of past depressive episodes was 1.3 ± 0.8 in the BLT group and 1.5 ± 0.8 in the SSRI + BLT group. No significant difference was observed in terms of the mean onset of depression and number of past depressive episodes between the groups (P = 0.425 and P = 0.427, respectively).
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any of the rating scales used in our study. Table 1 shows the 17-item HAM-D, BDI, and MEQ scores in the BLT and SSRI + BLT groups before and after treatment. The analysis of the difference between the pre-and posttreatment scores revealed no significant difference between groups. Table 2 shows POMS scores in the BLT and SSRI + BLT groups before and after treatment. The analysis of the difference between these pre-and posttreatment scores revealed no significant difference between groups in any of the subgroups of the POMS scores. Table 3 shows PSQI scores in the BLT and SSRI + BLT groups before and after the treatment. The analysis of the difference between pre-and posttreatment scores revealed no significant difference between groups in any subgroup of PSQI scores.
Discussion
To our knowledge, this is the first study that examines the effect of BLT on sleep quality as well as on mood, in nonseasonal depression. Our study results revealed that there was no evidence in favor of adjunctive fluoxetine with BLT for the treatment of non-seasonal depression, for any of the rating scales used. For the BLT group, the results showed that depressive symptom severity decreased after BLT, in all the HAM-D, BDI, MEQ scales, while the POMS total mood disturbance score showed a positive effect, and sleep quality increased in the PSQI scales. For the SSRI + BLT group, the depressive symptom scores measured in the HAM-D and BDI decreased, but the MEQ revealed worsened (although not significantly) results. Also, the POMS subscale scores of vigor and the PSQI component scores for subjective sleep quality, sleep duration, sleep efficiency, and use of sleep medication were worsened, but this difference was not significant. None of our patients experienced any obvious side effects. A core biological clock mechanism, residing in the SCN within the anterior hypothalamus, regulates circadian rhythms in the brain and body of mammals. The periodicity of these endogenous rhythms is continuously synchronized or entrained by environmental signals, primarily the light-dark cycle. Desynchronization of the normal circadian rhythms, including the sleep-wake rhythm, is common in major depressive disorder. 21 Manipulation of circadian rhythms either using BLT or behavioral therapy has shown promise in improving symptoms.
BLT represents a potent, nonpharmacological treatment modality whose efficacy and tolerability have been a matter of extensive research. Studies in the 1990s became the basis of a widely cited benchmark for BLT with light intensities of up to 10,000 lux and duration of 30 min/day. 22 Evidence 23 suggests that the melatonergic (MT [1] and MT [2] ) and the 5-Hydroxytryptamine (5HT2C) serotonergic receptor subtypes are important modulators of circadian rhythmicity. Melanopsin, a short-wavelength, light-sensitive G-proteincoupled receptor located in human retinal ganglion cells, is known to transduce short-wavelength light signals into neural signals. 24 Since melanopsin is primarily responsible for resetting the timing of the SCN, suppressing pineal melatonin secretion, and for improving alertness and the electroencephalogram-derived correlates of arousal, it has been hypothesized that short-wavelength light with a low light intensity might be a stimulator for melanopsin-containing retinal ganglion cells and the behaviors mediated via this photoreceptor system. 25 A meta-analysis on the efficacy of BLT was published by Golden et al in 2005 and systematically gathered efficacy data following the principles of evidence-based medicine. 26 The authors initiated a systematic review of all existing data from trials using BLT in seasonal and non-seasonal depression, from trials using dawn simulation for SAD, and from trials using BLT as adjunctive therapy to psychopharmacological treatment in non-seasonal depression. Of 173 studies, 23 qualified for inclusion into the meta-analysis. The results showed effects were impressive, equivalent or superior to most psychopharmacological trials. With regard to sleep quality, the present study showed (although not significantly) that BLT was effective in improving sleep quality, in accordance with mood changes. The suppression of melatonin secretion by BLT in the early morning hours may result in an improvement in mood states, including depression. On the other hand, BLT also causes a phase advance in circadian rhythms and an improvement in sleep quality. Terman and Terman found that 2500-lux light exposure for at least 2 hours/day for 1 week resulted in significantly higher remission when administered in the early morning compared with administration in the evening or at midday. 27 Three studies were able to conclusively demonstrate that early morning administration of BLT was associated with higher remission rates than was evening administration. 26−30 In the present study, BLT was administered for 30 minutes as soon as possible after awakening, between 7:00 am and 8:00 am.
With regard to BLT for non-seasonal depression, there is no consensus with respect to optimal timing, dosage, and treatment duration. We chose 1 week of daily light exposure like other studies that used short-term treatment of up to 1 week to report their findings. 31, 32 Furthermore, a Cochrane review of studies of BLT in non-seasonal affective disorder concluded that BLT may be effective in as little as 1 week. 33 Generally, BLT is well tolerated and well accepted by patients. 3, 4 Side effects are rare and tend to remit spontaneously or after dose reduction. The most common side effects are headache, eyestrain, nausea, and agitation. Evening administration of BLT can increase the incidence of sleep disturbances. 34 Suicidality may sporadically occur early in the treatment course, and menstrual irregularities have also been reported. 35 In the present study, none of the patients reported obvious side effects, and none dropped out of the treatment protocol. There were no hospitalizations or suicides during the study period. Although there is some evidence for retinal degeneration after prolonged exposure to intensive visible light in rodents, this was not confirmed in humans. 35 Nevertheless, patients with a family history of retinal damage or patients needing photosensitizing medication are advised to consult their ophthalmologist before initiating treatment. We excluded patients who had retinal disease or a family history that precluded the use of bright light from the study group.
Some caveats and limitations in our study should be noted. First, we limited our focus to an open study rather than a placebo-controlled study. Second, a placebo effect cannot be excluded since there was no control group in this trial (in trials of BLT, it is difficult to design a control group that is blind to both researchers and patients). Thus, the raters were also not blind to the conditions. Third, although the therapeutic drug regimen in the SSRI + BLT group was standardized, the duration of the treatment was not similar in each patient. Finally, our study includes a relatively small sample size, and generalization of the findings is relatively difficult.
As a conclusion, this study suggests that BLT was effective with respect to the severity of depression, circadian rhythms, mood disturbance, and sleep quality in non-seasonal depression. However, there was no evidence in favor of the use of adjunctive fluoxetine with BLT in the treatment of non-seasonal depression, for any of the rating scales used in our study. Future research is needed to examine objective sleep electroencephalogram (EEG) variables in patients with non-seasonal depression.
